Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]F-PSMA-N5 vs [18F]F-PSMA-1007 in Prostate Cancer
NCT06462495Phase 1Recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Apr 2024
- Primary completion
- Jun 2025
- Modality
- Antibody-Radionuclide Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [18F]F-PSMA-N5 in prostate cancer (PCa), sponsored by The First Affiliated Hospital of USTC. Primary endpoint: Standard Uptake Value at 30 days. Started Apr 2024; status: recruiting.
02
Drugs
[18F]F-PSMA-N5
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06462495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06462495.